AbbVie, schizophrenia

Advantage BMS as AbbVie drug fails schizophrenia trials
If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended a 10-year hiatus in new-mechanism therapies for the disorder when it got FDA approval for Cobenfy (xanomeline tartrate/trospium chloride) in September. Shares in BMS rose nearly 12% after AbbVie's announcement.
AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies
Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two Phase 2 trials.
Leerink upgrades Bristol to Outperform after AbbVie schizophrenia failure
Leerink analyst David Risinger upgraded Bristol Myers (BMY) to Outperform from Market Perform with a price target of $73, up from $55. The firm
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.
Bristol-Myers Hits 14-Month High After AbbVie’s Schizophrenia Drug Fails, Boosting Retail Sentiment
Bristol Myers Squibb ($BMY) stock rocketed over 11% in early morning trading on Monday to hit a 14-month high of $61.08 after AbbVie's ($ABBV) experimental schizophrenia treatment failed in a pair of mid-stage studies.
Is the FDA contributing to the homelessness crisis?
The FDA’s REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...
FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Zacks.com on MSN2h
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback
The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...
Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
AbbVie declines after missing main goal in schizophrenia treatment trials
AbbVie (ABBV) shares dropped 11% premarket as late-stage trials for schizophrenia drug emraclidine did not meet primary ...
BioPharma Dive8d
With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC
The president-elect has said he’ll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change ...
BioSpace4d
AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails Phase II Trials
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
The Hindu23d
FDA approval for Cobenfy casts light on schizophrenia’s wickedness
On September 26, the U.S. Food and Drug Administration (FDA) approved a drug called Cobenfy to treat schizophrenia. Cobenfy is a combination of xanomeline and trospium chloride that has a novel ...
STAT1d
AbbVie’s stumble, Amgen’s tumble, and more election fallout
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...